NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 164)
Posted On: 06/20/2023 4:04:11 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21. The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods for Treating Hypertension. Lexaria believes these two hypertension-related patents could be of particular importance related to its pursuit of utilizing DehydraTECH-CBD in relation to its expected upcoming FDA Investigational New Drug application.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21. The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods for Treating Hypertension. Lexaria believes these two hypertension-related patents could be of particular importance related to its pursuit of utilizing DehydraTECH-CBD in relation to its expected upcoming FDA Investigational New Drug application.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)